KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clover Health Investments (CLOV) Cash & Equivalents (2019 - 2025)

Clover Health Investments (CLOV) has disclosed Cash & Equivalents for 7 consecutive years, with $78.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 59.75% year-over-year to $78.3 million, compared with a TTM value of $78.3 million through Dec 2025, down 59.75%, and an annual FY2025 reading of $78.3 million, down 59.75% over the prior year.
  • Cash & Equivalents was $78.3 million for Q4 2025 at Clover Health Investments, down from $190.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $485.7 million in Q2 2021 and bottomed at $35.8 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $229.5 million, with a median of $205.3 million recorded in 2021.
  • Peak annual rise in Cash & Equivalents hit 159483.42% in 2021, while the deepest fall reached 68.18% in 2021.
  • Year by year, Cash & Equivalents stood at $300.0 million in 2021, then plummeted by 65.4% to $103.8 million in 2022, then rose by 18.38% to $122.9 million in 2023, then surged by 58.34% to $194.5 million in 2024, then crashed by 59.75% to $78.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for CLOV at $78.3 million in Q4 2025, $190.1 million in Q3 2025, and $188.6 million in Q2 2025.